17968 Federal Register / Vol. 76, No. 62 / Thursday, March 31, 2011 / Notices 

Drug Schedule 

Methylphenidate (1724) ................ II 

Fentanyl (9801) ............................ II 

The company plans to import the 

listed controlled substances in finished 

dosage form (FDF) from foreign sources 

for analytical testing and clinical trials 

in which the foreign FDF will be 

compared to the company’s own 

domestically-manufactured FDF. This 

analysis is required to allow the 

company to export domesticallymanufactured FDF to foreign markets. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a), 

and determined that the registration of 

Mylan Pharmaceuticals, Inc. to import 

the basic classes of controlled 

substances is consistent with the public 

interest, and with United States 

obligations under international treaties, 

conventions, or protocols in effect on 

May 1, 1971. DEA has investigated 

Mylan Pharmaceuticals, Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: March 21, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–7545 Filed 3–30–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated November 1, 2010, 

and published in the Federal Register 

on November 12, 2010, 75 FR 69460, GE 

Healthcare, 3350 North Ridge Avenue, 

Arlington Heights, Illinois 60004–1412, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

Cocaine (9041), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to import small 

quantities of ioflupane, in the form of 

three separate analogues of Cocaine, to 

validate production and quality control 

systems, for a reference standard, and 

for producing material for a future 

investigational new drug (IND) 

submission. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

GE Healthcare to import the basic class 

of controlled substance is consistent 

with the public interest and with United 

States obligations under international 

treaties, conventions, or protocols in 

effect on May 1, 1971. DEA has 

investigated GE Healthcare to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: March 21, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–7544 Filed 3–30–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated August 2, 2010, and 

published in the Federal Register on 

September 1, 2010, (75 FR 53720), 

Austin Pharma LLC., 811 Paloma Drive, 

Suite A, Round Rock, Texas 78665– 

2402, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

Alphamethadol (9605) .................. I 

Nabilone (7379) ............................ II 

Methadone (9250) ........................ II 

Methadone Intermediate (9254) ... II 

Levo-alphacetylmethadol (9648) .. II 

Alfentanil (9737) ........................... II 

Drug Schedule 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

In reference to drug code 7360 

(Marihuana), the company plans to bulk 

manufacture cannabidiol as a synthetic 

intermediate. This controlled substance 

will be further synthesized to bulk 

manufacture a synthetic THC (7370). No 

other activity for this drug code is 

authorized for this registration. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Austin Pharma LLC. to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Austin Pharma LLC. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: March 21, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–7540 Filed 3–30–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated August 13, 2010, and 

published in the Federal Register on 

September 1, 2010, 75 FR 53719, 

Cambrex Charles City, Inc., 1205 11th 

Street, Charles City, Iowa 50616, made 

application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

Gamma Hydroxybutyric Acid (GHB) 

(2010), a basic class of controlled 

substance listed in schedule I. 

The company plans to manufacture 

Gamma Hydroxybutyric Acid (GHB) 


wwoods2 on DSK1DXX6B1PROD with NOTICES
Federal Register / Vol. 76, No. 62 / Thursday, March 31, 2011 / Notices 17969 

(2010) in bulk active pharmaceutical 

ingredient (API) form for distribution to 

the company’s customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Cambrex Charles City, Inc. to 

manufacture the listed basic class of 

controlled substance is consistent with 

the public interest at this time. DEA has 

investigated Cambrex Charles City, Inc. 

to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: March 21, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–7539 Filed 3–30–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated November 1, 2010, 

and published in the Federal Register 

on November 12, 2010, 75 FR 69464, 

Cerilliant Corporation, 811 Paloma 

Drive, Suite A, Round Rock, Texas 

78665–2402, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of the following 

basic classes of controlled substances: 

Drug Schedule 

Cathinone (1235) ........................ I 

Methcathinone (1237) ................. I 

N-Ethylamphetamine (1475) ....... I 

N,N-Dimethylamphetamine 

(1480).

I 

Aminorex (1585) ......................... I 

4-Methylaminorex (cis isomer) 

(1590).

I 

Gamma-Hydroxybutyric acid 

(2010).

I 

Methaqualone (2565) ................. I 

Alpha-ethyltryptamine (7249) ..... I 

Lysergic acid diethylamide 

(7315).

I 

Drug Schedule 

2,5-Dimethoxy-4-(n)- 

propylthiophenethylamine 

(7348).

I 

Marihuana (7360) ....................... I 

Tetrahydrocannabinols (7370) .... I 

Mescaline (7381) ........................ I 

3,4,5-Trimethoxyamphetamine 

(7390).

I 

4-Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4-Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4-Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5-Dimethoxyamphetamine 

(7396).

I 

2,5-Dimethoxy-4- 

ethylamphetamine (7399).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

5-Methoxy-3,4- 

methylenedioxyamphetamine 

(7401).

I 

N-Hydroxy-3,4- 

methylenedioxyamphetamine 

(7402).

I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

3,4- 

Methylenedioxymethamphetamine (7405).

I 

4-Methoxyamphetamine (7411) .. I 

Alpha-methyltryptamine (7432) .. I 

Bufotenine (7433) ....................... I 

Diethyltryptamine (7434) ............ I 

Dimethyltryptamine (7435) ......... I 

Psilocybin (7437) ........................ I 

Psilocyn (7438) ........................... I 

5-Methoxy-N,Ndiisopropyltyptamine (7439).I 

N-Benzylpiperazine (7493) ......... I 

Acetyldihydrocodeine (9051) ...... I 

Benzylmorphine (9052) .............. I 

Codeine-N-oxide (9053) ............. I 

Dihydromorphine (9145) ............. I 

Heroin (9200) .............................. I 

Hydromorphinol (9301) ............... I 

Methyldihydromorphine (9304) ... I 

Morphine-N-oxide (9307) ............ I 

Normorphine (9313) ................... I 

Pholcodine (9314) ...................... I 

Acetylmethadol (9601) ................ I 

Allylprodine (9602) ...................... I 

Alphacetylmethadol except levoalphacetylmethadol (9603).I 

Alphameprodine (9604) .............. I 

Alphamethadol (9605) ................ I 

Betacetylmethadol (9607) ........... I 

Betameprodine (9608) ................ I 

Betamethadol (9609) .................. I 

Betaprodine (9611) ..................... I 

Hydroxypethidine (9627) ............ I 

Noracymethadol (9633) .............. I 

Norlevorphanol (9634) ................ I 

Normethadone (9635) ................ I 

Trimeperidine (9646) .................. I 

Phenomorphan (9647) ................ I 

1–Methyl-4-phenyl-4- 

propionoxypiperidine (9661).

I 

Tilidine (9750) ............................. I 

Para-Fluorofentanyl (9812) ......... I 

3–Methylfentanyl (9813) ............. I 

Alpha-Methylfentanyl (9814) ....... I 

Drug Schedule 

Acetyl-alpha-methylfentanyl 

(9815).

I 

Beta-hydroxyfentanyl (9830) ...... I 

Beta-hydroxy-3-methylfentanyl 

(9831).

I 

Alpha-Methylthiofentanyl (9832) I 

3–Methylthiofentanyl (9833) ....... I 

Thiofentanyl (9835) ..................... I 

Amphetamine (1100) .................. II 

Methamphetamine (1105) .......... II 

Lisdexamfetamine (1205) ........... II 

Phenmetrazine (1631) ................ II 

Methylphenidate (1724) .............. II 

Amobarbital (2125) ..................... II 

Pentobarbital (2270) ................... II 

Secobarbital (2315) .................... II 

Glutethimide (2550) .................... II 

Nabilone (7379) .......................... II 

1-Phenylcyclohexylamine (7460) II 

Phencyclidine (7471) .................. II 

1- 

Piperidinocyclohexanecarbonitrile (8603).

II 

Alphaprodine (9010) ................... II 

Cocaine (9041) ........................... II 

Codeine (9050) ........................... II 

Dihydrocodeine (9120) ............... II 

Oxycodone (9143) ...................... II 

Hydromorphone (9150) .............. II 

Diphenoxylate (9170) ................. II 

Benzoylecgonine (9180) ............. II 

Ethylmorphine (9190) ................. II 

Hydrocodone (9193) ................... II 

Levomethorphan (9210) ............. II 

Levorphanol (9220) .................... II 

Isomethadone (9226) ................. II 

Meperidine (9230) ...................... II 

Meperidine intermediate-A 

(9232).

II 

Meperidine intermediate-B 

(9233).

II 

Meperidine intermediate-C 

(9234).

II 

Methadone (9250) ...................... II 

Methadone intermediate (9254) II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ......................... II 

Thebaine (9333) ......................... II 

Levo-alphacetylmethadol (9648) II 

Oxymorphone (9652) .................. II 

Noroxymorphone (9668) ............. II 

Racemethorphan (9732) ............. II 

Alfentanil (9737) ......................... II 

Sufentanil (9740) ........................ II 

Tapentadol (9780) ...................... II 

Fentanyl (9801) .......................... II 

The company plans to manufacture 

small quantities of the listed controlled 

substances to make reference standards 

which will be distributed to their 

customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Cerilliant Corporation to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Cerilliant Corporation to 


wwoods2 on DSK1DXX6B1PROD with NOTICES